Stay updated on Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.

Latest updates to the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedThe study page now displays 'Results Submitted' to indicate that trial results have been posted, replacing the previous 'No Results Posted' notification. The change clarifies the availability of outcomes for users reviewing the trial.SummaryDifference0.1%

- Check19 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check26 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 on the page.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice as well as the prior Revision: v3.4.1 banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check61 days agoChange DetectedAdds a site-wide funding/operating status notice and updates versioning to v3.4.1, removing the previous v3.4.0 note.SummaryDifference0.5%

- Check68 days agoChange DetectedShow glossary option added and capitalization adjustments for labels such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', along with a revision tag to v3.4.0. Deletions remove lowercase variants and revert to an older revision label (v3.3.4).SummaryDifference0.2%

Stay in the know with updates to Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Brentuximab Vedotin ± Nivolumab in CD30+ Lymphoma Clinical Trial page.